SlideShare ist ein Scribd-Unternehmen logo
1 von 3
Downloaden Sie, um offline zu lesen
U.S. Pharma Company Promotional
Spending Trends in New Media
October 2009 to September 2010
Top Brands Expenditure in New Media to Physicians
New-Media Average Monthly Expenditures, 2006 to 2010
Promotional Expenditures by New-Media Channel, Oct. 2009 to Sept. 2010
Updated: November 2010
© 2010 SK&A, A Cegedim Company
SK&A - 2601 Main Street, Suite 650 - Irvine, California 92614 - P: 800.752.5478 - F: 949.476.2168
Pharmaceutical companies are finding novel ways to promote their products to physicians and other
prescribers, namely through new media channels such as internet detailing, tele-detailing, e-meetings
and web advertising. Pfizer’s depression drug, Pristiq, and Merck’s asthma product, Singulair, were
among the top drug brands receiving the largest budget allocations for these new media channels. With
the exception of Lescol and Nucynta, all of the products promoted through new media also rank overall
in top expenditures in pharmaceutical promotion (they are in top 100 in total promotional spending).
Source: Cegedim Strategic Data, based on ongoing survey panel of 2,455 physicians and other healthcare
practitioners. For more information about subscribing to Cegedim’s monthly Promotion Data reports, please
contact: Ayala Rom, Project Analyst: 201-984-3785 or ayala.rom@cegedim.com
Over the last four years, promotional spending in new media has increased significantly from about $5
million in January 2006 to about $26 million by September 2010. Traditional forms of promotion, such as
face-to-face detailing and meetings, are becoming less commonplace, while internet media such as e-
detailing and e-meetings are growing at a fast and steady pace.
In the U.S., promotional spending totaled $24 billion between October 2009 and September 2010. Of
the $24 billion spent in promotion of pharmaceutical products, $327 million was invested in new media.
New forms of detailing made up 84 percent, or $276 million, of new-media spending. These two new
detailing channels, tele-detailing and e-detailing, in combination have grown over 600 percent since
2006. Further, meetings are also a key promotion channel in the pharmaceutical industry; $48 million
was spent on e-meetings, a new, growing channel in pharmaceutical promotion. Finally, web advertising
(targeted to physicians), which is growing but at a much slower pace than other new forms of detailing
or meetings, made up one percent of spending in new media.
Source: Cegedim Strategic Data, based on ongoing survey panel of 2,455 physicians and other healthcare
practitioners. For more information about subscribing to Cegedim’s monthly Promotion Data reports, please
contact: Ayala Rom, Project Analyst: 201-984-3785 or ayala.rom@cegedim.com
U.S. Promotional Spending Oct 2009 to Sept 2010
New Media Channel Spending $ mil % of New Media Spending
Telephone Detailing 160 49%
Internet Detailing 116 35%
E-Meeting (Internet) 48 15%
Web Advertising to Physicians 4 1%
Total New Media Spending 327 100%
New Media Average Monthly Spending
2006-2010

Weitere ähnliche Inhalte

Was ist angesagt?

Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022PhRMA
 
The Pharma & ACO Relationship
The Pharma & ACO RelationshipThe Pharma & ACO Relationship
The Pharma & ACO RelationshipJoseph Gaspero
 
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...IMS Health US
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019PhRMA
 
Pharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsPharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsJatin Arora
 
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022PhRMA
 
Androgenetic alopecia treatment market analysis
Androgenetic alopecia treatment market analysisAndrogenetic alopecia treatment market analysis
Androgenetic alopecia treatment market analysisAkshay Shinde
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020PhRMA
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018PhRMA
 
2019 Election| Drug Program| Pharmacare| Canada | June 2019
2019 Election| Drug Program| Pharmacare| Canada | June 20192019 Election| Drug Program| Pharmacare| Canada | June 2019
2019 Election| Drug Program| Pharmacare| Canada | June 2019paul young cpa, cga
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021PhRMA
 
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...Visiongain
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019PhRMA
 
Oncologics Spending Reached $43.4 billion in 2014
Oncologics Spending Reached $43.4 billion in 2014 Oncologics Spending Reached $43.4 billion in 2014
Oncologics Spending Reached $43.4 billion in 2014 IMS Health US
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019PhRMA
 
mckesson Letter to Stockholders 2004
mckesson Letter to Stockholders 2004mckesson Letter to Stockholders 2004
mckesson Letter to Stockholders 2004finance2
 

Was ist angesagt? (19)

Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022
 
The Pharma & ACO Relationship
The Pharma & ACO RelationshipThe Pharma & ACO Relationship
The Pharma & ACO Relationship
 
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
 
Pharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsPharmaceutical Industry Analytics
Pharmaceutical Industry Analytics
 
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
 
Androgenetic alopecia treatment market analysis
Androgenetic alopecia treatment market analysisAndrogenetic alopecia treatment market analysis
Androgenetic alopecia treatment market analysis
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
 
2019 Election| Drug Program| Pharmacare| Canada | June 2019
2019 Election| Drug Program| Pharmacare| Canada | June 20192019 Election| Drug Program| Pharmacare| Canada | June 2019
2019 Election| Drug Program| Pharmacare| Canada | June 2019
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
 
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
Medco (MHS) Bench
Medco (MHS) BenchMedco (MHS) Bench
Medco (MHS) Bench
 
Oncologics Spending Reached $43.4 billion in 2014
Oncologics Spending Reached $43.4 billion in 2014 Oncologics Spending Reached $43.4 billion in 2014
Oncologics Spending Reached $43.4 billion in 2014
 
A0330108
A0330108 A0330108
A0330108
 
How should a national drug plan look (and cost)?
How should a national drug plan look (and cost)?How should a national drug plan look (and cost)?
How should a national drug plan look (and cost)?
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
 
mckesson Letter to Stockholders 2004
mckesson Letter to Stockholders 2004mckesson Letter to Stockholders 2004
mckesson Letter to Stockholders 2004
 

Andere mochten auch

Projet Alliadis Mon Pharma
Projet Alliadis Mon PharmaProjet Alliadis Mon Pharma
Projet Alliadis Mon PharmaPharmaSuccess
 
Présentation DocDoku
Présentation DocDokuPrésentation DocDoku
Présentation DocDokuDocDoku
 
Informe Farmaindustria 2009
Informe Farmaindustria 2009Informe Farmaindustria 2009
Informe Farmaindustria 2009Óscar Miranda
 
What next for mobile local search?
What next for mobile local search?What next for mobile local search?
What next for mobile local search?Martin Wilson
 
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)Mobile Web Company Core Principles When Thinking Mobile (Dec 09)
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)Martin Wilson
 
The science of content marketing
The science of content marketingThe science of content marketing
The science of content marketingSylvie Dale
 

Andere mochten auch (10)

Projet Alliadis Mon Pharma
Projet Alliadis Mon PharmaProjet Alliadis Mon Pharma
Projet Alliadis Mon Pharma
 
Présentation DocDoku
Présentation DocDokuPrésentation DocDoku
Présentation DocDoku
 
Informe Farmaindustria 2009
Informe Farmaindustria 2009Informe Farmaindustria 2009
Informe Farmaindustria 2009
 
What next for mobile local search?
What next for mobile local search?What next for mobile local search?
What next for mobile local search?
 
Nine Days in New York City
Nine Days in New York CityNine Days in New York City
Nine Days in New York City
 
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)Mobile Web Company Core Principles When Thinking Mobile (Dec 09)
Mobile Web Company Core Principles When Thinking Mobile (Dec 09)
 
Making the most of language assistants
Making the most of language assistantsMaking the most of language assistants
Making the most of language assistants
 
Arboleda International (English)
Arboleda International (English)Arboleda International (English)
Arboleda International (English)
 
Flowers
FlowersFlowers
Flowers
 
The science of content marketing
The science of content marketingThe science of content marketing
The science of content marketing
 

Ähnlich wie New media trends_cegedim

The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketingFarhad Zargari
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-reportpatyi_2000
 
Health 2.0 Quarterly Report (Q2 2016)
Health 2.0 Quarterly Report (Q2 2016) Health 2.0 Quarterly Report (Q2 2016)
Health 2.0 Quarterly Report (Q2 2016) health2dev
 
Big data revolution_in_health_care_2013_mc_kinsey_report
Big data revolution_in_health_care_2013_mc_kinsey_reportBig data revolution_in_health_care_2013_mc_kinsey_report
Big data revolution_in_health_care_2013_mc_kinsey_reportkate hong
 
A2-3, McKinsey view - The_big_data_revolution_in_healthcare (1)
A2-3, McKinsey view  - The_big_data_revolution_in_healthcare (1)A2-3, McKinsey view  - The_big_data_revolution_in_healthcare (1)
A2-3, McKinsey view - The_big_data_revolution_in_healthcare (1)Tom Pettersson
 
The 'big data' revolution in healthcare Mckinsey Report
The 'big data'  revolution in healthcare Mckinsey Report The 'big data'  revolution in healthcare Mckinsey Report
The 'big data' revolution in healthcare Mckinsey Report Healthcare consultant
 
MANA Healthcare Marketing Report 2015_FINAL
MANA Healthcare Marketing Report 2015_FINALMANA Healthcare Marketing Report 2015_FINAL
MANA Healthcare Marketing Report 2015_FINALMANA LLC
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9Yousaf Khan
 
Global market size in drug lead and precursor
Global market size in drug lead and precursorGlobal market size in drug lead and precursor
Global market size in drug lead and precursorPriya Saraf
 
Pharmaceutical Marketing - Whats in store for patients?
Pharmaceutical Marketing - Whats in store for patients?Pharmaceutical Marketing - Whats in store for patients?
Pharmaceutical Marketing - Whats in store for patients?brandsynapse
 
The Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismThe Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismDavid Vequist
 
Baja California, Mexico´s Medical Device Manufacturing Center
Baja California, Mexico´s Medical Device Manufacturing CenterBaja California, Mexico´s Medical Device Manufacturing Center
Baja California, Mexico´s Medical Device Manufacturing CenterTijuana Economic Development Corp
 
White Paper - Internet Marketing Strategies For The Medical Device Industry
White Paper - Internet Marketing Strategies For The Medical Device IndustryWhite Paper - Internet Marketing Strategies For The Medical Device Industry
White Paper - Internet Marketing Strategies For The Medical Device Industryjerryme5
 
2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...
2014 01   Boris Azais - How Pharmaceutical companies are transforming for the...2014 01   Boris Azais - How Pharmaceutical companies are transforming for the...
2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...Boris Azaïs
 
The 10 companies booming in healthcare sector small
The 10 companies booming in healthcare sector  smallThe 10 companies booming in healthcare sector  small
The 10 companies booming in healthcare sector smallinsightscare
 
2014_Healthcare_Marketing_Report_FINAL.pdf
2014_Healthcare_Marketing_Report_FINAL.pdf2014_Healthcare_Marketing_Report_FINAL.pdf
2014_Healthcare_Marketing_Report_FINAL.pdfMANA LLC
 
2015-annual-investment-report
2015-annual-investment-report2015-annual-investment-report
2015-annual-investment-reportCheryl Matter
 
Final Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVUFinal Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVUAaron Weese
 

Ähnlich wie New media trends_cegedim (20)

The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-report
 
Health 2.0 Quarterly Report (Q2 2016)
Health 2.0 Quarterly Report (Q2 2016) Health 2.0 Quarterly Report (Q2 2016)
Health 2.0 Quarterly Report (Q2 2016)
 
MEDTECH 2014 Opening Keynote
MEDTECH 2014 Opening KeynoteMEDTECH 2014 Opening Keynote
MEDTECH 2014 Opening Keynote
 
Big data revolution_in_health_care_2013_mc_kinsey_report
Big data revolution_in_health_care_2013_mc_kinsey_reportBig data revolution_in_health_care_2013_mc_kinsey_report
Big data revolution_in_health_care_2013_mc_kinsey_report
 
A2-3, McKinsey view - The_big_data_revolution_in_healthcare (1)
A2-3, McKinsey view  - The_big_data_revolution_in_healthcare (1)A2-3, McKinsey view  - The_big_data_revolution_in_healthcare (1)
A2-3, McKinsey view - The_big_data_revolution_in_healthcare (1)
 
The 'big data' revolution in healthcare Mckinsey Report
The 'big data'  revolution in healthcare Mckinsey Report The 'big data'  revolution in healthcare Mckinsey Report
The 'big data' revolution in healthcare Mckinsey Report
 
MANA Healthcare Marketing Report 2015_FINAL
MANA Healthcare Marketing Report 2015_FINALMANA Healthcare Marketing Report 2015_FINAL
MANA Healthcare Marketing Report 2015_FINAL
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
Life Sciences Trends 2014
Life Sciences Trends 2014Life Sciences Trends 2014
Life Sciences Trends 2014
 
Global market size in drug lead and precursor
Global market size in drug lead and precursorGlobal market size in drug lead and precursor
Global market size in drug lead and precursor
 
Pharmaceutical Marketing - Whats in store for patients?
Pharmaceutical Marketing - Whats in store for patients?Pharmaceutical Marketing - Whats in store for patients?
Pharmaceutical Marketing - Whats in store for patients?
 
The Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismThe Economic Impact Of Medical Tourism
The Economic Impact Of Medical Tourism
 
Baja California, Mexico´s Medical Device Manufacturing Center
Baja California, Mexico´s Medical Device Manufacturing CenterBaja California, Mexico´s Medical Device Manufacturing Center
Baja California, Mexico´s Medical Device Manufacturing Center
 
White Paper - Internet Marketing Strategies For The Medical Device Industry
White Paper - Internet Marketing Strategies For The Medical Device IndustryWhite Paper - Internet Marketing Strategies For The Medical Device Industry
White Paper - Internet Marketing Strategies For The Medical Device Industry
 
2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...
2014 01   Boris Azais - How Pharmaceutical companies are transforming for the...2014 01   Boris Azais - How Pharmaceutical companies are transforming for the...
2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...
 
The 10 companies booming in healthcare sector small
The 10 companies booming in healthcare sector  smallThe 10 companies booming in healthcare sector  small
The 10 companies booming in healthcare sector small
 
2014_Healthcare_Marketing_Report_FINAL.pdf
2014_Healthcare_Marketing_Report_FINAL.pdf2014_Healthcare_Marketing_Report_FINAL.pdf
2014_Healthcare_Marketing_Report_FINAL.pdf
 
2015-annual-investment-report
2015-annual-investment-report2015-annual-investment-report
2015-annual-investment-report
 
Final Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVUFinal Campaign for IMC 618 at WVU
Final Campaign for IMC 618 at WVU
 

Mehr von Óscar Miranda

Us tmt social software for business_031011
Us tmt  social software for business_031011Us tmt  social software for business_031011
Us tmt social software for business_031011Óscar Miranda
 
Us tmt social software for business_031011
Us tmt  social software for business_031011Us tmt  social software for business_031011
Us tmt social software for business_031011Óscar Miranda
 
2010 internet use_trends
2010 internet use_trends2010 internet use_trends
2010 internet use_trendsÓscar Miranda
 
2010 internet use_analysis
2010 internet use_analysis2010 internet use_analysis
2010 internet use_analysisÓscar Miranda
 
Redes socialesops v230211 Latinoamerica
Redes socialesops v230211 LatinoamericaRedes socialesops v230211 Latinoamerica
Redes socialesops v230211 LatinoamericaÓscar Miranda
 
Az social media_white_paper
Az social media_white_paperAz social media_white_paper
Az social media_white_paperÓscar Miranda
 
La Sociedad de la Información, Telefónica 2010
La Sociedad de la Información, Telefónica 2010La Sociedad de la Información, Telefónica 2010
La Sociedad de la Información, Telefónica 2010Óscar Miranda
 
Izo twitter-engage-01-2011
Izo twitter-engage-01-2011Izo twitter-engage-01-2011
Izo twitter-engage-01-2011Óscar Miranda
 
Leveraging social media for pharmaceutical companies
Leveraging social media for pharmaceutical companiesLeveraging social media for pharmaceutical companies
Leveraging social media for pharmaceutical companiesÓscar Miranda
 
Sanidad pacientes web_2_0
Sanidad pacientes web_2_0Sanidad pacientes web_2_0
Sanidad pacientes web_2_0Óscar Miranda
 
Ifhp price report2010_comparativepricereport29112010
Ifhp price report2010_comparativepricereport29112010Ifhp price report2010_comparativepricereport29112010
Ifhp price report2010_comparativepricereport29112010Óscar Miranda
 
informe biocat_2009_es
informe biocat_2009_esinforme biocat_2009_es
informe biocat_2009_esÓscar Miranda
 
Valoracion financiacion gasto sanitario Fundación BBVA
Valoracion financiacion gasto sanitario Fundación BBVAValoracion financiacion gasto sanitario Fundación BBVA
Valoracion financiacion gasto sanitario Fundación BBVAÓscar Miranda
 
Informe sectorial 2010 sanidad
Informe sectorial 2010   sanidadInforme sectorial 2010   sanidad
Informe sectorial 2010 sanidadÓscar Miranda
 
2010 european trends in aggregate spend, transparency and disclosure
2010 european trends in aggregate spend, transparency and disclosure2010 european trends in aggregate spend, transparency and disclosure
2010 european trends in aggregate spend, transparency and disclosureÓscar Miranda
 

Mehr von Óscar Miranda (20)

Bcg espanaconecta
Bcg espanaconectaBcg espanaconecta
Bcg espanaconecta
 
Us tmt social software for business_031011
Us tmt  social software for business_031011Us tmt  social software for business_031011
Us tmt social software for business_031011
 
Us tmt social software for business_031011
Us tmt  social software for business_031011Us tmt  social software for business_031011
Us tmt social software for business_031011
 
2010 internet use_trends
2010 internet use_trends2010 internet use_trends
2010 internet use_trends
 
2010 internet use_analysis
2010 internet use_analysis2010 internet use_analysis
2010 internet use_analysis
 
Pricing healthcare
Pricing healthcarePricing healthcare
Pricing healthcare
 
Dic2000
Dic2000Dic2000
Dic2000
 
Mar2002
Mar2002Mar2002
Mar2002
 
Redes socialesops v230211 Latinoamerica
Redes socialesops v230211 LatinoamericaRedes socialesops v230211 Latinoamerica
Redes socialesops v230211 Latinoamerica
 
Az social media_white_paper
Az social media_white_paperAz social media_white_paper
Az social media_white_paper
 
Informe bernat soria
Informe bernat soriaInforme bernat soria
Informe bernat soria
 
La Sociedad de la Información, Telefónica 2010
La Sociedad de la Información, Telefónica 2010La Sociedad de la Información, Telefónica 2010
La Sociedad de la Información, Telefónica 2010
 
Izo twitter-engage-01-2011
Izo twitter-engage-01-2011Izo twitter-engage-01-2011
Izo twitter-engage-01-2011
 
Leveraging social media for pharmaceutical companies
Leveraging social media for pharmaceutical companiesLeveraging social media for pharmaceutical companies
Leveraging social media for pharmaceutical companies
 
Sanidad pacientes web_2_0
Sanidad pacientes web_2_0Sanidad pacientes web_2_0
Sanidad pacientes web_2_0
 
Ifhp price report2010_comparativepricereport29112010
Ifhp price report2010_comparativepricereport29112010Ifhp price report2010_comparativepricereport29112010
Ifhp price report2010_comparativepricereport29112010
 
informe biocat_2009_es
informe biocat_2009_esinforme biocat_2009_es
informe biocat_2009_es
 
Valoracion financiacion gasto sanitario Fundación BBVA
Valoracion financiacion gasto sanitario Fundación BBVAValoracion financiacion gasto sanitario Fundación BBVA
Valoracion financiacion gasto sanitario Fundación BBVA
 
Informe sectorial 2010 sanidad
Informe sectorial 2010   sanidadInforme sectorial 2010   sanidad
Informe sectorial 2010 sanidad
 
2010 european trends in aggregate spend, transparency and disclosure
2010 european trends in aggregate spend, transparency and disclosure2010 european trends in aggregate spend, transparency and disclosure
2010 european trends in aggregate spend, transparency and disclosure
 

New media trends_cegedim

  • 1. U.S. Pharma Company Promotional Spending Trends in New Media October 2009 to September 2010 Top Brands Expenditure in New Media to Physicians New-Media Average Monthly Expenditures, 2006 to 2010 Promotional Expenditures by New-Media Channel, Oct. 2009 to Sept. 2010 Updated: November 2010 © 2010 SK&A, A Cegedim Company SK&A - 2601 Main Street, Suite 650 - Irvine, California 92614 - P: 800.752.5478 - F: 949.476.2168
  • 2. Pharmaceutical companies are finding novel ways to promote their products to physicians and other prescribers, namely through new media channels such as internet detailing, tele-detailing, e-meetings and web advertising. Pfizer’s depression drug, Pristiq, and Merck’s asthma product, Singulair, were among the top drug brands receiving the largest budget allocations for these new media channels. With the exception of Lescol and Nucynta, all of the products promoted through new media also rank overall in top expenditures in pharmaceutical promotion (they are in top 100 in total promotional spending). Source: Cegedim Strategic Data, based on ongoing survey panel of 2,455 physicians and other healthcare practitioners. For more information about subscribing to Cegedim’s monthly Promotion Data reports, please contact: Ayala Rom, Project Analyst: 201-984-3785 or ayala.rom@cegedim.com
  • 3. Over the last four years, promotional spending in new media has increased significantly from about $5 million in January 2006 to about $26 million by September 2010. Traditional forms of promotion, such as face-to-face detailing and meetings, are becoming less commonplace, while internet media such as e- detailing and e-meetings are growing at a fast and steady pace. In the U.S., promotional spending totaled $24 billion between October 2009 and September 2010. Of the $24 billion spent in promotion of pharmaceutical products, $327 million was invested in new media. New forms of detailing made up 84 percent, or $276 million, of new-media spending. These two new detailing channels, tele-detailing and e-detailing, in combination have grown over 600 percent since 2006. Further, meetings are also a key promotion channel in the pharmaceutical industry; $48 million was spent on e-meetings, a new, growing channel in pharmaceutical promotion. Finally, web advertising (targeted to physicians), which is growing but at a much slower pace than other new forms of detailing or meetings, made up one percent of spending in new media. Source: Cegedim Strategic Data, based on ongoing survey panel of 2,455 physicians and other healthcare practitioners. For more information about subscribing to Cegedim’s monthly Promotion Data reports, please contact: Ayala Rom, Project Analyst: 201-984-3785 or ayala.rom@cegedim.com U.S. Promotional Spending Oct 2009 to Sept 2010 New Media Channel Spending $ mil % of New Media Spending Telephone Detailing 160 49% Internet Detailing 116 35% E-Meeting (Internet) 48 15% Web Advertising to Physicians 4 1% Total New Media Spending 327 100% New Media Average Monthly Spending 2006-2010